Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | HTR1D | P28221 | 2/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7894748 | 0.97 | LMNA (0.42) | HRH3HTR1DRAPGEF4LMNAALDH1A1 | |
| Carbamic Acid SCHEMBL28102259 | 0.86 | LMNA (0.44) | LMNAALDH1A1KDM4EGAAMAPT | |
| SCHEMBL17888169 | 0.83 | HTR1D (0.38) | HRH3HTR1DRAPGEF4LMNAALDH1A1 | |
| SCHEMBL26566694 | 0.83 | TSHR (0.38) | HRH3HTR1DRAPGEF4LMNAALDH1A1 | |
| SCHEMBL5739986 | 0.83 | SELL (0.44) | HRH3HTR1DLMNAALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL29238261 | 0.81 | LMNA (0.36) | HRH3HTR1DRAPGEF4LMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL29197434 | 0.81 | LMNA (0.36) | HRH3HTR1DRAPGEF4LMNAALDH1A1 | |
| SCHEMBL15874052 | 0.80 | HTR1D (0.38) | HRH3HTR1D | |
| SCHEMBL17442579 | 0.80 | ALDH1A1 (0.43) | HTR1DLMNAALDH1A1KDM4EMAPT | |
| SCHEMBL9600773 | 0.79 | CNR1 (0.34) | HRH3HTR1DRAPGEF4LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116948646-A | Super-wetting buffer oxide etching solution, preparation method and application thereof | 浙江奥首材料科技有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-111704575-B | Synthesis method of quinoline-2-thiocarboxamide compound under conditions of no catalyst and no additive | 衡阳师范学院 | 2023-06-09 | — | — | CN | claimed |
| CN-111704575-A | Method for synthesizing quinoline-2-thiocarbamide compound under conditions of no catalyst and no additive | 衡阳师范学院 | 2020-09-25 | — | — | CN | claimed |
| US-9884839-B2 | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 | ELEXOPHARM GMBH (DE) | 2018-02-06 | — | — | US | claimed |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | ELEXOPHARM GMBH (DE) | 2016-11-03 | — | — | US | claimed |
| EP-1610779-B1 | 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | claimed |
| US-12297176-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-05-13 | — | — | US | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-117886734-A | Heterocyclic amide compound and preparation method, pharmaceutical composition and application thereof | 中国药科大学 | 2024-04-16 | — | — | CN | disclosed |
| EP-3559012-B1 | METAL ORGANIC COMPOUNDS | UMICORE AG & CO KG (DE) | 2023-11-01 | — | — | EP | disclosed |
| CN-116948646-A | Super-wetting buffer oxide etching solution, preparation method and application thereof | 浙江奥首材料科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-111704575-B | Synthesis method of quinoline-2-thiocarboxamide compound under conditions of no catalyst and no additive | 衡阳师范学院 | 2023-06-09 | — | — | CN | disclosed |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-20 | — | — | US | disclosed |
| EP-0240890-B1 | Prostacyclin (PGI2) analogues | SHIONOGI & CO (JP) | 1993-11-18 | — | — | EP | disclosed |
| US-4855449-A | Prostacyclin (PGI2) analogues | SHIONOGI & CO., LTD. (JP) | 1989-08-08 | — | — | US | disclosed |
| US-4820836-A | ANTICOAGULANTS, ANTIULCER AGENTS | SHIONOGI & CO., LTD. (JP) | 1989-04-11 | — | — | US | disclosed |
| EP-0240890-A2 | Prostacyclin (PGI2) analogues | SHIONOGI & CO., LTD. (JP) | 1987-10-14 | — | — | EP | disclosed |
| US-4312861-A | Pharmaceutical compositions containing N-alkyl-N-(nuclearly-substituted) benzylamines having vasotonia-regulating activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-01-26 | — | — | US | disclosed |
| US-4241052-A | ANTILEUKEMIC AND ANTICARCINOGENIC AGENTS | TANABE SEIYAKU CO., LTD. (JP) | 1980-12-23 | — | — | US | disclosed |
| US-3972773-A | ENZYME PEPSIN | SAGAMI CHEMICAL RESEARCH CENTER (JA) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297176-B2 | Compounds and methods for inhibiting EMT pathways to treat cancer, organ fibrosis and metabolic disorders | HGF, SMAD3, HRAS | HRH3 1079/4885HTR1D 4230/4885RAPGEF4 1247/4885 |
| US-20160318895-A1 | Inhibitors of 17Beta-Hydroxysteroid Dehydrogenases Type 1 and Type 2 | HSD17B1, HSD17B2, HSD17B3 | HRH3 3341/4885HTR1D 856/4885RAPGEF4 4401/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | HRH3 168/4885HTR1D 962/4885RAPGEF4 2643/4885 |
| US-20220017466-A1 | COMPOUNDS AND METHODS FOR INHIBITING EMT PATHWAYS TO TREAT CANCER, ORGAN FIBROSIS AND METABOLIC DISORDERS | HGF, SMAD3, HRAS | HRH3 1079/4885HTR1D 4230/4885RAPGEF4 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.